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BACKGROUND: Tumour necrosis factor (TNF) is capable of activating the cell death pathway, and has been implicated in killing
transformed cells. However, TNF also activates survival signals, including NF-kB activation and the subsequent expression of anti-
apoptotic genes, leading to protection against TNF toxicity.
METHODS: In this study, we show that, although untransformed mouse embryonic fibroblasts (MEFs) were resistant to TNF killing,
E1A/Ras-transformed MEFs were susceptible to extensive apoptosis induced by TNF. The key factors for determining TNF sensitivity
were explored by comparing wild-type and E1A/Ras-transformed MEFs.
RESULTS: TNF signalling to NF-kB and to its target genes such as IkBa seemed to be mostly intact in E1A/Ras-transformed cells.
Instead, the induction of A20 was completely abolished in E1A/Ras-transformed MEFs, although A20 is known to be NF-kB
dependent. Reintroduction of A20 into E1A/Ras-transformed MEFs rescued these cells from TNF-induced death and reduced the
formation of the FADD/caspase-8 complex. This impaired A20 induction in E1A/Ras MEFs was not because of the stabilisation of p53
or a defective TNF-induced p38 and Jun N-terminal kinase (JNK) signalling. Consistently, we found a reduced A20 promoter activity
but normal NF-kB activity in TNF-treated E1A/Ras MEFs. However, Bcl-3 seemed to have a role in the transactivation of the A20
promoter in E1A/Ras cells.
CONCLUSIONS: Our results suggest that specific inhibition of certain survival factors, such as A20, may determine the sensitivity to
TNF-induced apoptosis in transformed cells such as E1A/Ras MEFs.
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Tumour necrosis factor (TNF) is a pro-inflammatory cytokine that
induces cell death in sarcoma cells but not in untransformed
mouse embryonic fibroblasts (MEFs) (Carswell et al, 1975). Studies
of downstream signalling pathways, particularly those mediated by
TNF receptor 1 (TNFR1), reveal that TNF can induce both death
and survival pathways (Hsu et al, 1996; Mak and Yeh, 2002).
Exactly how these death and survival signals interact to determine
cell fate remains ambiguous.
Activation of NF-kB by TNF and expression of specific proteins
downstream of NF-kB seem to have a crucial role in TNF-induced
survival signals (Rubin et al, 1988; Beg and Baltimore, 1996; Van
Antwerp et al, 1996; Wang et al, 1996). Several NF-kB-inducible,
antiapoptotic proteins have been identified, including TNFR-
associated factors (TRAFs), inhibitors of apoptosis (IAPs), Bcl-2
family proteins, platelet-derived growth factor B (PDGF-B), and
A20, which seem to act in a cooperative manner for cell survival
(Opipari et al, 1992; Wang et al, 1998; Yeh et al, 1999; Baetu et al,
2001). The IAPs and Bcl-2 family proteins are direct antagonists of
the activation of caspases and apoptotic machinery, and the
terminal cytotoxic processes induced by TNF are thereby shut
down. Other proteins, such as PDGF-B, do not seem to directly
interfere with the death machinery, and their exact anti-apoptotic
mechanisms remain to be elucidated.
A clue to understanding how cell death or survival outcomes are
determined after TNF stimulation comes from studies of the TNF-
induced protein complex assembly. It was established that binding
of TNF initiates protein–protein interactions between TNFR1 and
the TNFR-associated death domain protein (TRADD). TRADD in
turn recruits receptor-interacting protein (RIP) and TRAF2 for
NF-kB and survival signals, or recruits the Fas-associated death
domain protein (FADD) for apoptotic execution (Hsu et al, 1995,
1996; Chen and Goeddel, 2002; Mak and Yeh, 2002). This laid the
foundation for TNF signalling dichotomy, supported by genetic
evidence that deficiency of one set of signals results in the
dominance of the other pathway (Yeh et al, 1997, 1998).
Recently, a more detailed analysis of protein signalling
complexes induced by TNF/TNFR1 binding reveals that two major
complexes can potentially be assembled after TNF stimulation
(Micheau and Tschopp, 2003). Complex I, composed of TNFR1,
TRADD, RIP1, TRAF2, and other accessory proteins, is rapidly
assembled in the lipid rafts of plasma membrane upon TNF
binding, and is responsible for activating NF-kB. Within 1 hour of
binding, the cytoplasmic components of Complex I then dissociate
Received 3 April 2009; revised 1 September 2009; accepted 9
September 2009; published online 13 October 2009
*Correspondence: Dr H-L Huang, Department of Bioscience Technol-
ogy, College of Health Science, Chang Jung Christian University, Tainan
71101, Taiwan, ROC; E-mail: hhuang@mail.cjcu.edu.tw
British Journal of Cancer (2009) 101, 1555–1564
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sfrom TNFR1, allowing the interaction of TRADD/RIP1/TRAF2
with FADD and caspase-8, with a subsequent formation of
Complex II. Notably, Complex II is readily formed on TNF
stimulation in Ras-transformed human fibrosarcoma cells (Legler
et al, 2003; Micheau & Tschopp, 2003). In these cells, the activation
of caspase-8 within Complex II is the major turning point for cell
fate in response to TNF.
In this study, we analysed the signalling in normal TNF-resistant
MEFs and TNF-sensitive MEFs that were transformed by E1A and
Ras. Frequently found in human cancers, constitutively active Ras
induces senescence, but cooperates with other oncoproteins such
as adenoviral E1A and c-Myc to transform primary human and
rodent cells (Ruley, 1983; Serrano et al, 1997). Comparison
between untransformed and transformed MEFs revealed a specific
defect of A20 induction by TNF stimulation in E1A/Ras-
transformed cells, despite the normal NF-kB activation and IkBa
induction. In addition, ectopic expression of A20 in transformed
MEFs rescued the cells from TNF-induced death, suggesting that
A20 may regulate the original signalling complex assembled by
TNF stimulation (Wertz et al, 2004). Furthermore, we identified
a role of Bcl-3 in TNF-induced A20 expression, which was
dysregulated in E1A/Ras-transformed MEFs. Our results uncov-
ered a novel and potentially critical imbalance within transformed
cells because of the lack of key survival factor(s) such as A20 and/
or possibly A20-like proteins, thereby allowing the formation of a
death-inducing complex when stimulated with TNF.
MATERIALS AND METHODS
Cell culture and E1A/Ras-transformed MEFs
MEFs were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum (Gibco, Grand Island,
NY, USA) and 50mM b-mercaptoethanol (Gibco). To prepare
transformed MEFs, E1A and Ras were expressed using pLPC or
pBabe retroviral vectors, which were kindly provided by Drs Scott
W Lowe (Cold Spring Harbor, NY, USA) and Miria Soengas
(University of Michigan Comprehensive Cancer Center) as
described (Berube et al, 2005). Briefly, MEFs were infected with
retrovirus-containing culture supernatant from transfected
Phoenix packaging cells. For pLPC (McCurrach et al, 1997), cells
grown in puromycin (2mgml
 1) medium for 7 days were selected.
The p53
þ/þ and p53
 / E1A/Ras MEFs were also gifts from
Dr Scott Lowe (Lowe et al, 1994). For the A20 or Bcl-3 stable
expression MEFs, pBabe retroviral vector, and pBabeA20 or
pBabeBcl-3 were used for retroviral production; then E1A/Ras
MEFs (for A20) or wild-type MEFs (for Bcl-3) were infected with
retrovirus and selected using puromycin as described above. For
A549 E1A/Ras cells (Figure 1D), human A549 epithelial cells were
cultured in 10% serum-containing F-12 medium (Gibco) and were
infected with E1A/Ras gene-containing retrovirus culture super-
natant. TNF sensitivity was tested 2–6 days after transduction.
Plasmids
Human Bcl-3 cDNA (Open BioSystems, Huntsville, AL, USA) was
subcloned into pBabe retroviral vector digested with BamHI and
SalI. For the antisense Bcl-3 used in Figure 8B, an inverted
orientation of the Bcl-3 fragment (757–232), as previously
described (Brasier et al, 2001), was generated by RT–PCR and
cloned into pcDNA4. Both murine p50 and p52 cDNA were
generated by RT–PCR using total cDNA as template from wild-
type MEFs. The PCR primers used are as follows: p50 50-g
cagacgatgatccctacgg-30 and 50-ctatatggtgccatgggtgacc-30; p52 50-ga
caattgctacgatccaggc-30 and 50- tcacgtctagaaccggccatc-30. After
sequence confirmation, both cDNA fragments were inserted into
pBabe retroviral vector (Figure 8A) or p4SV40 vector (Figure 8C;
CMV promoter in pcDNA4 was replaced with the SV40 promoter
from pBabe).
Cell death assay
After incubation with 10ngml
 1 recombinant TNFa (R&D system,
Minneapolis, MN, USA) plus 0 to 0.1mgml
 1 CHX (Sigma) for
9–16h, attached and suspended MEFs cells were collected and
resuspended in phosphate-buffered saline (PBS) containing
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Figure 1 Selective TNF sensitivity in E1A/Ras-transformed MEFs.
(A) Total cell lysates from WT or E1A/Ras-transformed MEFs were
immunoblotted with E1A and Ras antibodies. (B and C) E1A/Ras-
transformed MEFs were sensitive to TNF-induced cell death. WT or E1A/
Ras-transformed MEFs were treated with 10ngml
 1 TNF plus 0, 0.025, or
0.1mgml
 1 CHX (TNF plus 0.1mgml
 1 CHX for Figure 1B) for 16h, and
the percentage of viable cells was analysed by flow cytometry. (D) A549
epithelial cells were first transduced with vector- or E1A/Ras-containing
viruses; thereafter, cells were left untreated or treated with 10ngml
 1 TNF
plus 0, 0.1, or 0.25mgml
 1 CHX (as indicated) for 24h. Viable
cells were detected by MTS assay, and the relative percentage of viable
cells (percentage of survival) was calculated as follows: [mean OD
(treated)/mean OD (untreated)] 100.
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s1mgml
 1 propidium iodide (Sigma, St Louis, MO, USA). The
percentage of viable cells was detected and analysed by flow
cytometry (FACSCalibur, Becton Dickenson, Mountain View, CA,
USA). For the detection of apoptosis by fragmented nuclei
observation, MEFs were cultured on coverglasses coated with
poly-L-lysine (Sigma). After TNFa and CHX treatment for 14h,
cells were washed, fixed with 3.7% formaldehyde/PBS, stained with
40, 6-diamidino-2-phenyindole (DAPI; Sigma), and finally ob-
served using a confocal laser-scanning microscope (Zeiss). For
A549 E1A/Ras cells in Figure 1D, the relative percentage of viable
cells was detected and analysed by MTS assay (Promega, Madison,
WI, USA), according to the manufacturer’s instructions.
Northern blot analysis
Total RNA from MEFs was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA), resolved on 1% denaturing
formaldehyde agarose gels, and transferred to Hybond N
membranes (GE Healthcare, Milwaukee, WI, USA) (Yeh et al,
2000). cDNA probes for A20, IkBa, and GAPDH were used to
hybridise with the blots. For Figure 6B, wild-type MEFs were
pretreated for 1h with 25mM of the p38 inhibitor SB203580 or the
JNK inhibitor II (Calbiochem, La Jolla, CA, USA), before being
treated with TNFa.
Immunoprecipitation (i.p.) and western blot analysis
After TNF treatment, MEFs were dissolved in RIPA buffer (PBS
containing 0.1% SDS, 1% NP-40, and 0.5% Sodium deoxycholate)
with protease inhibitors (Roche Biochemicals, Indianapolis, IN,
USA) for FADD i.p. reactions. After removal of debris by
centrifugation, lysates were immunoprecipitated with FADD anti-
serum (kindly provided by D Goeddel, Z Cao, and G Chen, Tularik,
South San Francisco), and were washed 5 times. Immunoprecipitates
were resuspended in sample buffer, subjected to 10% SDS–PAGE,
and immunoblotted with FADD (Upstate, Lake Placid, NY, USA) and
Caspase-8 (Alexis, San Diego, CA, USA) antibodies for the same
blots. The following antibodies were also used for straight western
blot analysis: cFLIP (Apotech, San Diego, CA, USA), IkB (Cell
Signaling, Beverly, MA, USA or Santa Cruz, Santa Cruz, CA, USA),
Bcl-2, c-IAP2 (Santa Cruz), XIAP (BD Biosciences, Mountain View,
CA, USA), phospho-p38, phospho-JNK, phosphor-ERK, ERK (Cell
Signaling), p38, and JNK2 (Santa Cruz).
Gel mobility shift assays and oligonucleotide pull-down
assays
Gel mobility shift assays were performed as previously described
(Yeh et al, 1997). Nuclear extracts were purified from untreated or
TNFa-and CHX-treated MEFs , and consensus NF-kB probes were
used for these assays. Similar to gel mobility shift assays, the NF-
kB probe-associated NF-kB family members from nuclear extracts
were checked by oligonucleotide pull-down assays (Bundy and
McKeithan, 1997; Budunova et al, 1999; Corn et al, 2005) as
follows: We used biotinylated oligonucleotides of the NF-kB
binding site from human A20 promoter. The sequences were
(sense) 50-GTGACTTTGGAAAGTCCCGTGGAAATCCCCGGGC-30
and (antisense) 50-GCCCGGGGATTTCCACGGGACTTTCCAAAG
TCAC-30. Equal amounts of both nucleotides were first annealed as
dsDNA probe. Nuclear extracts prepared as above were mixed with
biotinylated dsDNA probe on ice for 1h, then incubated for
another 2h with streptavidin-agarose beads (Sigma) in binding
buffer (20mM HEPES pH7.8, 50mM KCl, 0.2mM EDTA, 1.5mM
MgCl2, 1mM DTT, 0.25% Triton, and 10% glycerol). After this
pull-down reaction, beads were washed with binding buffer
and kB probe-bound proteins were subjected to 9% SDS–PAGE
and immunoblotted with the following antibodies: p65, p50,
Bcl-3 (Santa Cruz), p100/52 (Cell Signaling), and Hsc70 for the
same blots.
Luciferase activity assay
HEK293 cells or MEFs were seeded into 24-well (for 293 cells) or
12-well (for MEFs) plates 1 day before transfection. The same
amounts of A20-Luc reporter plasmid (kindly provided by
Dr Rivka Dikstein (Ainbinder et al, 2002)) and pCMVbGal were
co-transfected with 2- to 4-fold of plasmids (such as Bcl-3, as
indicated in Figures 6–8) into HEK293 cells using Superfect
(Qiagen, Indianapolis, IN, USA) or into MEFs using Fugene 6
(Roche, Indianapolis, IN, USA). Two days later, cells were left
untreated or treated 6h with human or murine TNFa 10ngml
 1
(for 293 or MEFs, respectively) in the absence of CHX. After the
cells were washed with PBS, luciferase activity in cell lysates was
detected using the Luciferase Assay System (Promega) according
to the manufacturer’s instructions, and was normalised to
b-galactosidase activity (Yeh et al, 1997, 2000).
RESULTS
Expression of many anti-apoptotic proteins is unaffected
in TNF-sensitive MEFs transformed by E1A/Ras
Interaction of FADD and caspase-8 with TNFR signalling proteins
is an essential feature in transformed fibrosarcoma cells on TNF
stimulation (Micheau and Tschopp, 2003). For comparison
between TNF-sensitive transformed MEFs and TNF-resistant
wild-type MEF cells, we generated transformed MEFs by over-
expression of E1A and Ras (Figure 1A). E1A/Ras-transformed cells
were more sensitive to cell death induced by TNF, and this
cytotoxicity became even more prominent if cells were treated with
TNF plus a trace amount of cycloheximide (CHX, 0.025 or
0.1mgml
 1), as shown in Figures 1B and 1C. Untransformed MEFs
were not affected by the treatment of TNF plus 0.1mgml
 1 CHX
(Figure 1B), whereas the viability of E1A/Ras MEFs was severely
impaired.
To further extend our findings, we tested whether this
phenomenon is also true in epithelial cells (Figure 1D), particularly
those with established Ras oncogenic activity. We chose to use the
A549 cell line, which was reported to be insensitive to TNF-
induced toxicity in an earlier study (Sugarman et al, 1985). After
retrovirus-mediated vector or E1A/Ras expression, A549 epithelial
cells were treated with TNF alone or with TNF plus a trace amount
of CHX. Consistent with the MEF system, A549 E1A/Ras cells were
more sensitive to TNF killing when compared with cells expressing
vector alone (Figure 1D).
To investigate what could potentially account for TNF sensitivity
in E1A/Ras-transformed vs control wild-type MEFs, we examined
the expression of various anti-apoptotic proteins. cFLIP is a
protein that directly antagonises TNF- and other death factor-
induced apoptosis (Yeh et al, 2000) by interfering with the
activation of caspase-8. We found that expressions of cFLIPL,
cFLIPS, and the processed derivative of cFLIP (p43) did not seem
to be defective in E1A/Ras-transformed cells (Figure 2A). Instead,
by an unknown mechanism, the expression of cFLIPL and cFLIP
(p43) was slightly higher in transformed MEFs than in wild-type
MEFs. We further examined the expression of other anti-apoptotic
proteins including c-IAP2, XIAP, and Bcl-2. The expressions of
c-IAP2, XIAP, and Bcl-2, in the presence or absence of TNF
stimulation, were similar between untransformed and E1A/Ras-
transformed MEFs (Figure 2B), suggesting that the enhanced TNF
susceptibility of E1A/Ras MEFs was not because of the down-
regulation of these anti-apoptotic factors.
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in E1A/Ras MEFs
As the expression of survival genes induced by TNF is mostly NF-
kB dependent, we examined whether the increased TNF sensitivity
in E1A/Ras MEFs was caused by a perturbation of NF-kB
activation. As shown in Figure 3A, TNF-induced IkB degradation
proceeded normally in E1A/Ras MEFs, as compared with that in
wild-type cells. Measurement of DNA binding by gel mobility shift
assays also revealed that TNF-induced formation of the NF-kB–
DNA complex was not defective in E1A/Ras-transformed cells
(Figure 3B). A slight increase in NF-kB DNA-binding activity was
instead observed in E1A/Ras MEFs stimulated with TNF.
We next examined the expression of two NF-kB target genes
induced by TNF. Although TNF-induced IkBa mRNA expression was
unaffected in E1A/Ras-transformed cells, A20 mRNA induction was
totally abolished in these transformed cells (Figure 3C). The defect
was not restricted to a specific E1A/Ras-transformed cell line, as
similar results were found in several E1A/Ras-transformed MEF lines
that we generated (data not shown), or in the lines obtained from
other laboratories (for example, Dr Scott Lowe) (see 6B). The defect
was also evident in E1A/Ras-transformed MEFs treated with TNF
alone (independent of CHX; data not shown, also see 6B and 7B). As
A20 is implicated in the protection against TNF-induced apoptosis,
the specific defect in A20 induction may contribute to the TNF
sensitivity observed in E1A/Ras MEFs.
Reconstitution of A20 in E1A/Ras-transformed MEFs
protects cells from TNF toxicity
The process of E1A/Ras transformation is complicated and it is
likely that multiple events and changes are involved. To investigate
whether the absence of A20 induction has a key role in sensitising
cells to TNF-induced apoptosis, we restored the A20 expression in
E1A/Ras MEFs using retrovirus transfection. Compared with
parental or empty-vector-expressing cells, A20 stable expression
significantly rescued E1A/Ras-transformed MEFs from TNF-
induced cell death (Figure 4A and 4B). The same result was
observed in three independent A20-expressing E1A/Ras MEF cell
lines and in their controls (data not shown). We next examined
whether the formation of a complex containing FADD and
caspase-8 differed between these MEF lines. Assembled FADD-
associated protein complexes were examined by immunoprecipi-
tation, followed by western blotting. In addition to the full-length
caspase-8, the processed caspase-8 p43/41 was also associated with
FADD (Figure 4C), as reported previously (Micheau and Tschopp,
2003), in E1A/Ras-transformed MEFs. However, the TNF-induced
death signalling complex that co-immunoprecipitated with FADD
was decreased in A20-expressing E1A/Ras MEF cells (Figure 4C),
suggesting that A20 has a key role in guarding E1A/Ras-
transformed MEFs against TNF-induced cell death.
Furthermore, we observed that caspase-8 was processed in E1A/
Ras MEFs after TNF treatment, in contrast to wild-type MEF
(Figure 4D). Reconstitution with A20 delayed the degradation of
caspase-8 in E1A/Ras MEFs. Caspase-8 activation led to the
cleavage of BAP31 (Ng et al, 1997) and Bid (Mak and Yeh, 2002),
which was also suppressed by the reconstitution of A20
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s(Figure 4E). Taken together, our results suggest that the deficiency
of A20 induction in TNF-stimulated E1A/Ras MEFs is a key factor
contributing to their susceptibility to cell death mediated by TNF.
As A20 reconstitution did not completely revert cells to normal, it
is possible that other unidentified survival factors are also involved
in E1A/Ras MEFs.
JNK, p38, or p53 is not required to suppress A20
expression in E1A/Ras-transformed MEFs
We next investigated MAPK signalling pathways downstream of
TNF in these transformed MEFs. Intriguingly, TNF-induced p38
and JNK phosphorylations were also reduced in E1A/Ras-
transformed cells (Figure 5A), reminiscent of the phenomenon
observed in RIP /  MEFs (Devin et al, 2000). In contrast,
phosphorylations of ERK and Akt induced by TNF seemed similar
between wild-type and E1A/Ras MEFs (Figure 5A, data not shown),
except that basal phospho-ERK was enhanced in untreated
E1A/Ras MEFs probably because of constitutive Ras activity.
To further examine whether defective p38 or JNK signals affect
A20 inducibility, we stimulated wild-type MEFs with TNF in the
absence or presence of JNK or p38-specific inhibitors. As shown in
Figure 5B, inhibition of either the p38 or JNK pathway did not
completely shut down but delayed A20 induction by TNF. In
addition, co-treatment of both inhibitors only partially inhibited
A20 expression (data not shown). These data suggested that
although p38 and JNK pathways may have a role in A20
expression, the deficiency of A20 induction in TNF-stimulated
E1A/Ras MEFs was not entirely dependent on the defects of p38
and JNK in these cells.
Another possibility could be that expression of A20 was suppressed
by factors induced or upregulated by E1A/Ras transformation. As
E1A/Ras triggers signals that stabilise the p53 protein (Lowe et al,
1993, 1994), we thus investigated whether p53 inhibits the transcrip-
tional activation of the A20 promoter. As shown in Figure 6A, TNF-
induced A20 promoter activity was suppressed in the presence of p53.
However, p53 overexpression in this reporter/transfection setting also
suppressed the activation of the E-selectin promoter (ELAM), with
NF-kB as the major transcriptional element, and an artificial promoter
containing six tandem NF-kB-binding sites (6 NF-kB) (Yeh et al,
2000; Komarova et al, 2005). Therefore, p53 suppresses the activation
of the A20 promoter, as well as that of other kB-containing promoters.
If A20 expression was primarily inhibited by p53, most NF-kB-
mediated transactivation should also be blocked in E1A/Ras MEFs.
To further delineate the role of p53 in the inhibition of A20
expression, we examined the induction of A20 by TNF stimulation
in both p53
þ/þ and p53
 /  E1A/Ras-transformed MEFs. The
NF-kB target gene, IkBa, was induced by TNF in E1A/Ras MEF
cells with or without p53 (Figure 6B). A small increase in IkBa
expression was detected in p53-deficient E1A/Ras MEFs, suggest-
ing a relief of p53-mediated inhibition of IkBa expression.
However, expression of A20 was not restored in transformed cells
that lacked p53 (Figure 6B). These results suggested that p53 is not
the major factor responsible for the suppressed A20 induction in
E1A/Ras-transformed MEFs.
The role of Bcl-3 in the regulation of A20 expression
As the transcriptional activation of the A20 gene primarily depends
on NF-kB (Ainbinder et al, 2002), the defective A20 induction in
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(Figure 3). As shown in Figure 7A and consistent with Figure 3,
activation of NF-kB-driven promoters (ELAM and 6 NF-kB) was
in fact slightly higher in E1A/Ras MEFs than in wild-type controls
after TNF treatment. On the other hand, both untreated (basal
level) and TNF-induced activation of the A20 promoter were
severely compromised in E1A/Ras MEFs (Figure 7A). The control
of certain target genes may involve other NF-kB family members,
in addition to p65 and p50 (Natoli et al, 2005; Hoffmann et al,
2006; Hayden and Ghosh, 2008). We next investigated, by
comparing wild-type and E1A/Ras cells, which the NF-kB member
may interact with the kB binding site derived from A20 promoter
using oligonucleotide pull-down assay. Interestingly, we found that
A20 promoter binding by Bcl-3, but not by p65, p50, p52
(Figure 7B), or c-Rel (data not shown), was specifically defective
in E1A/Ras MEFs. The amount of Bcl-3 in nuclei of both wild-type
and E1A/Ras cells was similar. Intriguingly, Bcl-3 showed a
predominantly nuclear localisation in the presence or absence of
TNF in MEFs (data not shown) – similar to some earlier reports
(Bours et al, 1993; Zhang et al, 2000) but different from its
expression in keratinocytes (Massoumi et al, 2006).
Bcl-3 was found to be a co-activator of p50 and p52 for the
transactivation of cyclin D1, Bcl-2, GATA-3, etc. (Westerheide
et al, 2001; Viatour et al, 2003; Corn et al, 2005; Massoumi et al,
2006). To further examine whether Bcl-3 is involved in the
regulation of A20 expression, a transient overexpression of Bcl-3
was performed and activation of A20 promoter activity was
observed in transfected cells measured by luciferase activity
(Figure 8A). In contrast, antisense Bcl-3 seemed to reduce TNF-
induced A20 promoter activity in 293 cells (Figure 8B). We next
examined a Bcl-3 stably expressing MEF line and found that A20
promoter activity was increased with or without TNF stimulation
(Figure 8C and D). Similar to other Bcl-3 target genes, co-
transfection of p52 or p50 further enhanced A20 promoter activity
as shown in Figures 8A and 8C. Taken together, Bcl-3 is capable
of regulating the expression of A20 and may be one of the key
factors involved in differential TNF responses from wild-type and
E1A/Ras-transformed cells.
DISCUSSION
E1A/Ras-transformed cells are known to undergo cell death
induced by various stimuli, including chemotherapeutics and
TNF (Figure 1) (Ames et al, 1990; Yeh et al, 1998; Locksley et al,
2001). In this study, we demonstrated this phenomenon in MEFs
and epithelial cells (Figure 1D). Exactly why these cells are more
susceptible to TNF remains an important open question. In this
study, we compared untransformed and E1A/Ras-transformed
MEFs, and found that although TNF-induced NF-kB activation was
intact, induction of A20 was impaired in E1A/Ras-transformed
cells (Figure 9). This defect of A20 likely has a key role in the
susceptibility of these transformed cells to TNF, as reconstitution
of A20 partly protected E1A/Ras MEFs from TNF-induced cell
death. Interestingly, oestrogen receptor signalling can inhibit A20
expression, which correlates with the sensitivity of breast cancer
cells to tamoxifen with a better prognosis (Vendrell et al, 2007). In
addition, tamoxifen is capable of augmenting cytotoxicity to
TNF or to its related death factor TRAIL in breast cancer cells
(Tiwari et al, 1991; Lagadec et al, 2008). Another interesting study
(not cancer related) demonstrated the antiapoptotic role for A20 in
pancreatic b cells, as A20 is possibly the most highly regulated
anti-apoptotic gene stimulated by cytokines (Liuwantara et al,
2006). This is especially important for the correlation between
diabetes and cell death in insulin-producing b cells.
The exact mechanism of E1A/Ras suppression of A20 induction
remains to be determined. No significant defect in the activation of
NF-kB, a major transcription factor dictating A20 expression, was
observed in E1A/Ras-transformed MEFs (Figure 3A and 3B). There
was instead a small increase in NF-kB–DNA complex formation in
E1A/RasMEFs (Figure 3B). p53, which is important for Ras-
induced senescence and chemotherapy-induced apoptosis, is
thought to be stabilised in E1A/Ras MEFs (Lowe et al, 1993,
1994). In our experiments, p53 inhibited NF-kB activation
(Figure 4A), as previously reported (Komarova et al, 2005).
However, as p53 deficiency did not restore A20 induction in
E1A/Ras MEFs (Figure 4B), p53 does not seem to be the major
factor that inhibits A20 expression, although a lesser role for p53 in
suppressing A20 expression cannot be completely excluded. Along
the same line, overexpression of PML, a target and a collaborator
of p53, inhibits TNF-induced A20 expression in osteosarcoma
cells, and this inhibition correlates with the sensitivity of these cells
to TNF-induced apoptosis (Wu et al, 2002).
In addition to p53, we examined for other defective signalling
pathways that may affect A20 induction in E1A/Ras-transformed
MEFs. Interestingly, compared with wild-type MEFs,
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Figure 5 Abrogation of TNF-induced A20 expression is independent
of the reduced p38 or JNK signalling in E1A/Ras-transformed MEFs.
(A) Defective p38 and JNK signalling in E1A/Ras-transformed MEFs. Cells
as indicated in figures were left untreated or treated with TNF plus
0.1mgml
 1 CHX for 5–60min. Expression of phosphorylated or total ERK,
p38, and JNK in both cell lysates was detected by immunoblotting using
antibodies as indicated. (B) WT MEFs were pretreated with 25mM of
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Expression of A20 or I-kB mRNA was detected by northern blot analysis,
as shown in Figure 3C.
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in E1A/Ras-transformed MEFs (Figures 5A and 9). When wild-type
cells were pretreated with inhibitors against JNK or p38, A20
induction was mildly reduced or delayed. It is possible that
both JNK and p38, probably in combination with other
factors/pathways, have a role in the impaired induction of A20
in E1A/Ras-transformed MEFs. However, A20 expression does not
seem to strictly depend on these MAPK signalling pathways.
A20 has been implicated as a survival factor that antagonises
TNF-induced death (Opipari et al, 1992; Jaattela et al, 1996; De
Valck et al, 1999; Lademann et al, 2001). A20-knockout mice are
runted and highly sensitive to LPS- or TNF-induced toxicity
in vivo (Lee et al, 2000; Boone et al, 2004). Cells lacking A20 are
hypersensitive to TNF-induced cell death. It is possible that
induction of A20 by TNF represents a feedback inhibition event,
and A20 may interfere with further death signal progression by
interacting with protein(s) involved in TNF signalling. Indeed, A20
has been shown to interact with TRAF2 and NEMO in the TNF-
signalling complex (Zhang et al, 2000). A20 also contains dual
enzymatic activities of de-ubiquitination (from its OTU domain)
and E3 ubiquitin ligase (zinc finger) (Wertz et al, 2004; Heyninck
and Beyaert, 2005). It has been proposed that A20 is able to remove
K63-linked ubiquitin from RIP, which deactivates RIP and
prevents it from associating with the signalling protein complex,
and is also able to ubiquitinate RIP at the K48 residue, which
targets it for proteasome-mediated degradation.
The action of A20 is further complicated by its role in regulating
NF-kB activity induced by TNF and other pro-inflammatory
stimuli. A20-deficient animals and cells show phenotypes of
elevated NF-kB activities triggered by TNF or Toll-like receptors
(Lee et al, 2000; Boone et al, 2004), and overexpression of A20
inhibits NF-kB activation induced by TNF (Heyninck and Beyaert,
2005). Some of the key factors for NF-kB activation, including RIP
and TRAF6, may be substrates for A20, and A20 may control
NF-kB signalling activities by targeting these key proteins for
ubiquitination. Aberrant NF-kB activation has been associated
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swith the development of tumours (Karin, 2006). For example, loss
of CYLD, a key de-ubiquitinating enzyme that controls NEMO
function, has been linked to a predisposition to cylindroma
(Brummelkamp et al, 2003; Trompouki et al, 2003). It is thus
possible that loss of A20 may result in deregulated NF-kB activity,
which contributes to the abnormality of transformed cells.
E1A/Ras MEF cells exhibited moderately enhanced and prolonged
NF-kB activation when challenged with TNF (Figure 3B). How
the aberrant NF-kB activity affects these transformed MEF cells
remains to be investigated.
Hence if A20-deficient cells respond to TNF with a normal or
higher activity of NF-kB survival signal, why are they more
sensitive to TNF-induced apoptosis? This is an intriguing question
that remains to be investigated. One key factor determining the life
and death of cells after TNF stimulation is the successful assembly
of a death signalling complex (Complex II as referred to by a
report published by J Tschopp’s group) (Micheau and Tschopp,
2003). The formation of TNF-induced pro-apoptotic complex II
depends on the components of the earlier signalling complex
(Complex I). RIP is a component of TNF-induced signal complex I,
but it also participates in death signalling complex II formation.
Targeting RIP is expected to affect both NF-kB signal through
complex I and apoptosis induction through complex II. Because
A20 regulates RIP activity, there exists a possibility that the
phenotype seen with E1A/Ras MEFs in this study is because of a
de-regulation of RIP. The failure of TNF to induce A20 in E1A/Ras-
transformed cells may therefore lead to abnormal NF-kB activation
and enhanced assembly of the death signalling complex. Studies
are ongoing to delineate the molecular link between A20 and
complex II formation.
Another interesting question is how different NF-kB family
members cooperate to regulate a diversity of NF-kB target genes,
including A20 (Natoli et al, 2005; Hoffmann et al, 2006; Hayden
and Ghosh, 2008). In this study, we examined E1A/Ras-
transformed cells, in which A20 induction was abolished, and
found that binding of Bcl-3, but not of other NF-kB members, to
the A20 promoter site was defective. As Bcl-3 protein expressions
were abundant in both E1A/Ras and wild-type cells (Figure 7), the
apparent, specific defect of Bcl-3 binding to the A20 gene
regulatory site remains an interesting question for future studies.
Interestingly, small Jab1 complex is reduced in Ras-transformed
cells (Fukumoto et al, 2005). Deficiency of the Jab1 complex may
contribute to the poor binding of Bcl-3 to the A20 promoter in
E1A/Ras MEFs, as Jab1 was shown to enhance Bcl-3/p50 and the
DNA complex (Dechend et al, 1999). Similar to Bcl-2, Bcl-3 was
identified as an oncoprotein from chronic lymphocytic leukaemia
with a t(14;19) chromosome translocation (McKeithan et al, 1990).
As a member of the IkB family of proteins, Bcl-3 was shown to be a
transactivator for many genes, including cyclin D1, Bcl-2, and
GATA-3 (Westerheide et al, 2001; Viatour et al, 2003; Corn et al,
2005; Massoumi et al, 2006). Similar to these Bcl-3 target genes, we
showed here that Bcl-3 overexpression could induce A20 promoter
activity and that both p52 and p50 collaborated with Bcl-3 for A20
induction (Figure 8). Identification of Bcl-3 and other potential
regulators for A20 in transformed tumour cells may help advance
our understanding of the control of cell life and death induced by
death factors such as TNF.
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